# A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

> **NCT00531232** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 38 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Clofarabine

## Key facts

- **NCT ID:** NCT00531232
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05-07
- **Primary completion:** 2011-05-12
- **Final completion:** 2011-05-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531232, "A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00531232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*